Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1
作者：
Bolla, M. [1 ]
Fourneret, P. [1 ]
Descotes, J. -L. [2 ]
机构：
[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France
[2] CHU, Clin Univ Urol, F-63011 Grenoble, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷 / 12期
关键词：
high-risk prostate cancer; combination of external irradiation and androgen suppression;
D O I：
10.1684/bdc.2008.0755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.
引用
收藏
页码：1213 / 1218
页数：6
相关论文
共 37 条
[1]  
Bagshaw M A, 1988, NCI Monogr, P47
[2]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[3]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[4]  
BOLLA M, 2007, 43 ANN M CHIC P AM S, V25, pS18
[5]   Clinical stage T3 prostate cancer: The added value of three-dimensional conformal/intensity-modulated external-beam radiotherapy [J].
Bolla, Michel .
EUROPEAN UROLOGY, 2008, 53 (06) :1104-1106
[6]  
Bolla Michel, 2005, Cancer Radiother, V9, P394, DOI 10.1016/j.canrad.2005.07.006
[7]   Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer [J].
Bolla, Michel ;
Descotes, Jean-Luc ;
Artignan, Xavier ;
Fourneret, Philippe .
BJU INTERNATIONAL, 2007, 100 :44-47
[8]   Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate [J].
D'Amico, Anthony V. ;
Denham, James W. ;
Bolla, Michel ;
Collette, Laurence ;
Lamb, David S. ;
Tai, Keen-Hun ;
Steigler, Allison ;
Chen, Ming-Hui .
CANCER, 2007, 109 (10) :2004-2010
[9]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[10]   6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial [J].
D'Amico, AV ;
Manola, J ;
Loffredo, M ;
Renshaw, AA ;
DellaCroce, A ;
Kantoff, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07) :821-827
1234